258 related articles for article (PubMed ID: 17853922)
21. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.
Kambara H; Okano H; Chiocca EA; Saeki Y
Cancer Res; 2005 Apr; 65(7):2832-9. PubMed ID: 15805284
[TBL] [Abstract][Full Text] [Related]
22. The function of temporally ordered viral gene expression in the intracellular replication of herpes simplex virus type 1 (HSV-1).
Nakabayashi J; Sasaki A
J Theor Biol; 2009 Nov; 261(1):156-64. PubMed ID: 19660477
[TBL] [Abstract][Full Text] [Related]
23. Herpes simplex virus 1 (HSV-1) for cancer treatment.
Shen Y; Nemunaitis J
Cancer Gene Ther; 2006 Nov; 13(11):975-92. PubMed ID: 16604059
[TBL] [Abstract][Full Text] [Related]
24. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer.
Fu X; Tao L; Zhang X
Cancer Gene Ther; 2007 May; 14(5):480-7. PubMed ID: 17290283
[TBL] [Abstract][Full Text] [Related]
25. Bovine herpesvirus type 1 as a novel oncolytic virus.
Rodrigues R; Cuddington B; Mossman K
Cancer Gene Ther; 2010 May; 17(5):344-55. PubMed ID: 19893594
[TBL] [Abstract][Full Text] [Related]
26. Transcriptional activation of the human papillomavirus type 5 and 16 long control region in cells from cutaneous and mucosal origin.
Mistry N; Simonsson M; Evander M
Virol J; 2007 Mar; 4():27. PubMed ID: 17352804
[TBL] [Abstract][Full Text] [Related]
27. The 3' region of human papillomavirus type 16 early mRNAs decrease expression.
Vinther J; Rosenstierne MW; Kristiansen K; Norrild B
BMC Infect Dis; 2005 Oct; 5():83. PubMed ID: 16225671
[TBL] [Abstract][Full Text] [Related]
28. LAT expression during an acute HSV infection in the mouse.
Jarman RG; Wagner EK; Bloom DC
Virology; 1999 Sep; 262(2):384-97. PubMed ID: 10502517
[TBL] [Abstract][Full Text] [Related]
29. Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.
Kambara H; Saeki Y; Chiocca EA
Cancer Res; 2005 Dec; 65(24):11255-8. PubMed ID: 16357128
[TBL] [Abstract][Full Text] [Related]
30. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model.
Li H; Dutuor A; Fu X; Zhang X
J Gene Med; 2007 Mar; 9(3):161-9. PubMed ID: 17266169
[TBL] [Abstract][Full Text] [Related]
31. Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor.
Kamiyama H; Zhou G; Roizman B
Gene Ther; 2006 Apr; 13(7):621-9. PubMed ID: 16292350
[TBL] [Abstract][Full Text] [Related]
32. The herpes simplex virus type 1 vhs-UL41 gene secures viral replication by temporarily evading apoptotic cellular response to infection: Vhs-UL41 activity might require interactions with elements of cellular mRNA degradation machinery.
Barzilai A; Zivony-Elbom I; Sarid R; Noah E; Frenkel N
J Virol; 2006 Jan; 80(1):505-13. PubMed ID: 16352574
[TBL] [Abstract][Full Text] [Related]
33. Factors that limit the effectiveness of herpes simplex virus type 1 for treatment of oral cancer in mice.
Shillitoe EJ; Pellenz C
Clin Cancer Res; 2005 Apr; 11(8):3109-16. PubMed ID: 15837767
[TBL] [Abstract][Full Text] [Related]
34. A novel HSV-1 virus, JS1/34.5-/47-, purges contaminating breast cancer cells from bone marrow.
Hu JC; Booth MJ; Tripuraneni G; Davies D; Zaidi SA; Tamburo de Bella M; Slade MJ; Marley SB; Gordon MY; Coffin RS; Coombes RC; Kamalati T
Clin Cancer Res; 2006 Nov; 12(22):6853-62. PubMed ID: 17121907
[TBL] [Abstract][Full Text] [Related]
35. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus.
Fu X; Tao L; Cai R; Prigge J; Zhang X
Mol Ther; 2006 May; 13(5):882-90. PubMed ID: 16569513
[TBL] [Abstract][Full Text] [Related]
36. Effect of a caspase inhibitor, zVADfmk, on the inhibition of breast cancer cells by herpes simplex virus type 1.
Wood LW; Shillitoe EJ
Cancer Gene Ther; 2011 Oct; 18(10):685-94. PubMed ID: 21701533
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of HSV-1 and adenovirus vector-mediated infection, replication and cytotoxicity in lymphoma cell lines.
Zhang X; Zhao L; Hang Z; Guo H; Zhang M
Oncol Rep; 2011 Sep; 26(3):637-44. PubMed ID: 21567107
[TBL] [Abstract][Full Text] [Related]
38. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
Kohno SI; Luo C; Nawa A; Fujimoto Y; Watanabe D; Goshima F; Tsurumi T; Nishiyama Y
Cancer Gene Ther; 2007 Nov; 14(11):918-26. PubMed ID: 17693992
[TBL] [Abstract][Full Text] [Related]
39. Generation and use of recombinant reporter viruses for study of herpes simplex virus infections in vivo.
Bloom DC; Jarman RG
Methods; 1998 Sep; 16(1):117-25. PubMed ID: 9774521
[TBL] [Abstract][Full Text] [Related]
40. Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer.
Kohno S; Luo C; Goshima F; Nishiyama Y; Sata T; Ono Y
Urology; 2005 Nov; 66(5):1116-21. PubMed ID: 16286150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
